In the latest trading session,, 2.02 million ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) shares changed hands as the company’s beta touched 0.26. With the company’s most recent per share price at $0.47 changing hands around $0.0 or 0.81% at last look, the market valuation stands at $13.23M. IPA’s current price is a discount, trading about -453.19% off its 52-week high of $2.60. The share price had its 52-week low at $0.35, which suggests the last value was 25.53% up since then. When we look at ImmunoPrecise Antibodies Ltd’s average trading volume, we note the 10-day average is 0.34 million shares, with the 3-month average coming to 472.58K.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) trade information
Instantly IPA is in green as seen in intraday trades today. With action 20.47%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -72.29%, with the 5-day performance at 20.47% in the green. However, in the 30-day time frame, ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) is -16.88% down. Looking at the short shares, we see there were 0.67 million shares sold at short interest cover period of 0.73 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ImmunoPrecise Antibodies Ltd (IPA) estimates and forecasts
Data shows that the ImmunoPrecise Antibodies Ltd share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -58.74% over the past 6 months, a 61.54% in annual growth rate that is considerably higher than the industry average of 25.60%. Year-over-year growth is forecast to reach 0.50% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 4.63M. 2 analysts are of the opinion that ImmunoPrecise Antibodies Ltd’s revenue for the current quarter will be 4.82M.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -11.23%. The 2024 estimates are for ImmunoPrecise Antibodies Ltd earnings to increase by 55.39%.
IPA Dividends
ImmunoPrecise Antibodies Ltd is expected to release its next quarterly earnings report on 2024-Dec-12.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 12.06% of ImmunoPrecise Antibodies Ltd shares while 5.72% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 6.50%. There are 5.72% institutions holding the ImmunoPrecise Antibodies Ltd stock share, with INGALLS & SNYDER LLC the top institutional holder. As of 2024-06-30, the company held 5.0209% of the shares, roughly 1.3 million IPA shares worth $1.31 million.
RENAISSANCE TECHNOLOGIES LLC holds the second largest percentage of outstanding shares, with 0.2477% or 63910.0 shares worth $64549.0 as of 2024-06-30.
